Skip to main content

Table 1 Clinico-pathological characteristics of the patients

From: MDM2 gene SNP309 T/G and p53gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians

   analyzed
Patients characteristics all trial patients B 1/2 (n = 1399) NHL patients (n = 311) DLBCL patients (n = 205)
Age Median; yr (range) 75) 60 (18–75) 62 (23–75) 61 (23–75)
Sex    
   male 789 (56%) 175 (56%) 115 (56%)
   female 610 (44%) 136 (44%) 90 (44%)
International Prognostic Index (IPI)    
   Low (0,1) 840 (60%) 176 (57%) 118 (58%)
   Low intermediate (2) 250 (18%) 62 (20%) 42 (20%)
   High intermediate (3) 170 (12%) 46 (15%) 31 (15%)
   High (4,5) 139 (10%) 27 (9%) 14 (7%)
Risk Age    
   Age ≤ 60 yrs 710 (51%) 143 (46%) 98 (48%)
   Age > 60 yrs 689 (49%) 168 (54%) 107(52%)
Risk extranodal involvement    
   ≤ 1 ex. involvement 1123 (80%) 254 (82%) 174(85%)
   > 1 ex. involvement 276 (20%) 57 (18%) 31(15%)
Risk ECOG    
   ECOG 0,1 1236 (88%) 273 (88%) 178(87%)
   ECOG 2–4 163 (12%) 38 (12%) 27(13%)
Risk Stage    
   Stage I, II 832 (59%) 191 (61%) 134(65%)
   Stage III-IV 567 (41%) 120 (39%) 71(35%)
Risk LDH    
   LDH ≤ ONW 1083 (77%) 241 (77%) 160(78%)
   LDH > ONW 316 (23%) 70 (23%) 45(22%)
Bulky tumor (7.5 cm or larger) 467 (33%) 90 (29%) 62(30%)